Progyny, Inc. PGNY
Progyny is a global leader in women’s health and family building solutions. 10-K, Item 1
- Headquarters
- New York, NY
- CEO
- Peter Anevski
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $1.3B through the costs to a net profit of $58.5M · income statement of the 10-K
PGNY among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
4 new risk paragraphs. 10-K filed Feb 27, 2026 against Mar 3, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
10 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 10 checks found nothing to note
-
Receivables -6.4% ($235.3M to $220.3M) vs revenue +10.4% ($1.2B to $1.3B), -16.8 pts apart
-
Cash from operations $210.2M vs net income $58.5M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: Ernst & Young LLP
7 more checks with nothing to note
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Table of Contents; Accrued Receivables and Accrued Claims Payable
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
4 paragraphs in Risk Factors that were not in the 10-K filed Mar 3, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
The global economy has also been impacted by geopolitical tensions. There is currently significant uncertainty about future trade relationships between the United States and various other countries. Further escalation of specific trade tensions, or more broadly in global trade conflicts, could materially and adversely affect the…
-
Item 1A · new paragraph · not in the 10-K filed Mar 3, 2025 10-K, ITEM 1A
Our use of artificial intelligence may subject us to new or heightened legal, regulatory, ethical, operational or other challenges. We use, and may in the future continue to use, artificial intelligence (“AI”), including generative AI, in connection with our business and operations, including for internal operational and productivity…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $786.9M | $1.1B | $1.2B | $1.3B |
| Net income | $30.4M | $62.0M | $54.3M | $58.5M |
| Operating cash flow | $80.4M | $188.8M | $179.1M | $210.2M |
| Free cash flow | $77.2M | $185.2M | $173.7M | $191.8M |
Revenue, FY2017 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$1.3B ▲ 10.4% in FY2025$58.5M ▲ 7.7% in FY2025$191.8M ▲ 10.4% in FY2025
Recent filings
11 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 12, 2026Clapp Geoffrey (Officer) gave notice of a planned sale of 774 shares worth about $28K Form 144, approximate sale date Nov 11, 2026, under a 10b5-1 plan adopted Aug 12, 2026
-
Planned saleNov 10, 2026ANEVSKI 2026 SOUTH DAKOTA NGCG TR (Director, Officer) gave notice of a planned sale of 50,139 shares worth about $1.8M Form 144, approximate sale date Nov 10, 2026, under a 10b5-1 plan adopted Jul 2, 2026
-
Planned saleNov 5, 2026PETER ANEVSKI (Director, Officer) gave notice of a planned sale of 314,738 shares worth about $9.5M Form 144, approximate sale date Nov 5, 2026, under a 10b5-1 plan adopted Jul 2, 2026
-
Planned saleNov 5, 2026ANEVSKI 2026 SOUTH DAKOTA NGCG TR (Director, Officer) gave notice of a planned sale of 90,000 shares worth about $2.7M Form 144, approximate sale date Nov 5, 2026, under a 10b5-1 plan adopted Jul 2, 2026
-
Planned saleNov 5, 2026DAVID SCHLANGER (Director, Officer) gave notice of a planned sale of 200,000 shares worth about $6.0M Form 144, approximate sale date Nov 5, 2026, under a 10b5-1 plan adopted Jul 2, 2026
About the company
Progyny, Inc., New York, NY · from the 10-K filed Feb 27, 2026
Progyny is a global leader in women’s health and family building solutions. We envision a world where everyone can realize their dreams of family and ideal health. Our mission is to empower healthier, supported journeys through transformative fertility, family building and women’s health benefits. Through our differentiated approach to benefits plan design, member education and support and active network management, our clients’ employees are able to pursue the most effective treatment across life’s milestones from the best providers and specialists and achieve optimal outcomes.
- Headquarters
- New York, NY
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Mar 3, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PGNY/export.csv") into a cell.